Jack Allen
Stock Analyst at Robert W. Baird
(0.04)
# 4,500
Out of 4,517 analysts
332
Total ratings
30.7%
Success rate
-16.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jack Allen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TSHA Taysha Gene Therapies | Maintained: Buy | $12 → $15 | $6.19 | +142.33% | 27 | Jun 30, 2026 | |
| FTH Faeth Therapeutics | Initiated Coverage: Buy | $57 | $31.47 | +81.12% | 1 | Jun 26, 2026 | |
| LYEL Lyell Immunopharma | Initiated Coverage: Buy | $49 | $14.26 | +243.62% | 1 | May 1, 2026 | |
| NTLA Intellia Therapeutics | Maintained: Hold | $7 → $13 | $13.04 | -0.31% | 25 | Apr 27, 2026 | |
| ALLO Allogene Therapeutics | Maintained: Buy | $7 → $9 | $1.90 | +373.68% | 23 | Apr 14, 2026 | |
| RARE Ultragenyx Pharmaceutical | Maintained: Buy | $47 → $40 | $31.71 | +26.14% | 12 | Feb 13, 2026 | |
| TIL Instil Bio | Downgraded: Hold | $180 → $7 | $7.62 | -8.14% | 28 | Jan 7, 2026 | |
| MREO Mereo BioPharma Group | Maintained: Buy | $8 → $1 | $0.3279 | +204.97% | 5 | Dec 29, 2025 | |
| VOR Vor Biopharma | Maintained: Buy | $64 → $46 | $18.08 | +154.42% | 29 | Dec 23, 2025 | |
| CRSP CRISPR Therapeutics AG | Maintained: Hold | $52 → $44 | $51.37 | -14.35% | 13 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $1.22 | +309.84% | 20 | Sep 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 → $6 | $3.04 | +97.37% | 9 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 | $3.20 | n/a | 27 | Jul 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $5 → $4 | $2.99 | n/a | 11 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.0057 | n/a | 14 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $11.09 | n/a | 17 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $84 | $34.68 | n/a | 9 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 | $2.81 | n/a | 26 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $72 → $65 | $58.95 | n/a | 9 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $27 | $15.70 | n/a | 17 | Nov 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $200 → $25 | $13.03 | n/a | 9 | Sep 26, 2023 |
Taysha Gene Therapies
Jun 30, 2026
Maintained: Buy
Price Target: $12 → $15
Current: $6.19
Upside: +142.33%
Faeth Therapeutics
Jun 26, 2026
Initiated Coverage: Buy
Price Target: $57
Current: $31.47
Upside: +81.12%
Lyell Immunopharma
May 1, 2026
Initiated Coverage: Buy
Price Target: $49
Current: $14.26
Upside: +243.62%
Intellia Therapeutics
Apr 27, 2026
Maintained: Hold
Price Target: $7 → $13
Current: $13.04
Upside: -0.31%
Allogene Therapeutics
Apr 14, 2026
Maintained: Buy
Price Target: $7 → $9
Current: $1.90
Upside: +373.68%
Ultragenyx Pharmaceutical
Feb 13, 2026
Maintained: Buy
Price Target: $47 → $40
Current: $31.71
Upside: +26.14%
Instil Bio
Jan 7, 2026
Downgraded: Hold
Price Target: $180 → $7
Current: $7.62
Upside: -8.14%
Mereo BioPharma Group
Dec 29, 2025
Maintained: Buy
Price Target: $8 → $1
Current: $0.3279
Upside: +204.97%
Vor Biopharma
Dec 23, 2025
Maintained: Buy
Price Target: $64 → $46
Current: $18.08
Upside: +154.42%
CRISPR Therapeutics AG
Nov 11, 2025
Maintained: Hold
Price Target: $52 → $44
Current: $51.37
Upside: -14.35%
Sep 23, 2025
Reiterated: Buy
Price Target: $5
Current: $1.22
Upside: +309.84%
Aug 13, 2025
Maintained: Buy
Price Target: $10 → $6
Current: $3.04
Upside: +97.37%
Jul 17, 2025
Reiterated: Buy
Price Target: $18
Current: $3.20
Upside: n/a
May 14, 2025
Maintained: Hold
Price Target: $5 → $4
Current: $2.99
Upside: n/a
May 12, 2025
Rated: Hold
Price Target: n/a
Current: $0.0057
Upside: n/a
May 12, 2025
Rated: Hold
Price Target: n/a
Current: $11.09
Upside: n/a
Nov 6, 2024
Maintained: Buy
Price Target: $84
Current: $34.68
Upside: n/a
Nov 5, 2024
Maintained: Buy
Price Target: $10
Current: $2.81
Upside: n/a
Oct 30, 2024
Maintained: Hold
Price Target: $72 → $65
Current: $58.95
Upside: n/a
Nov 16, 2023
Maintained: Hold
Price Target: $27
Current: $15.70
Upside: n/a
Sep 26, 2023
Downgraded: Hold
Price Target: $200 → $25
Current: $13.03
Upside: n/a